{"id":55482,"date":"2023-04-04T09:04:38","date_gmt":"2023-04-04T07:04:38","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\/"},"modified":"2023-04-04T09:04:38","modified_gmt":"2023-04-04T07:04:38","slug":"labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\/","title":{"rendered":"LabGenius Appoints Prof Hendrik-Tobias Arkenau and Prof Victor Greiff as Scientific Advisors"},"content":{"rendered":"
\n

\nProminent oncology clinician Prof Hendrik-Tobias Arkenau and computational antibody design expert Prof Victor Greiff will bolster LabGenius’ leadership in the field of machine learning-driven antibody discovery.<\/p>\n

LONDON–(BUSINESS WIRE)–#AI<\/a>–LabGenius, a pioneer in the use of machine learning (ML) for antibody discovery, today announced that accomplished scientific leaders Hendrik-Tobias Arkenau<\/a>, MD\/PhD\/FRCP, and Victor Greiff<\/a>, PhD, will join their world-class team of advisors. As distinguished experts in academia and biotech, they will play an important role in advancing LabGenius\u2019 antibody discovery platform and its ability to discover next-generation oncology treatments.<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cThe calibre of these appointments demonstrates our unwavering commitment to accelerating the development of uniquely powerful antibody therapeutics,\u201d <\/i>says LabGenius\u2019 founder and CEO, James Field<\/a>. \u201cProf Greiff and Prof Arkenau\u2019s guidance will add to our ability <\/i>to make significant improvements to the existing therapeutic landscape.\u201d<\/i><\/p>\n

\nProf Arkenau is currently serving as Chief Medical Officer and Global Head of Drug Development at Ellipses Pharma and is a highly respected Consultant Medical Oncologist, practising at several HCA<\/a> locations alongside his honorary appointment at University College London. Prior to joining industry, Prof Arkenau was Executive Medical Director of the Sarah Cannon Research Institute where he led the development of multiple new cancer drugs ranging from small molecules to complex immunotherapies. As a skilled physician, he has extensive experience in early oncology drug development in many different tumour types. Prof Arkenau is currently helping LabGenius develop its scientific strategy relating to its pipeline of immune-cell engagers, which benefit from best-in-class killing selectivity.<\/p>\n

\n\u201cLabGenius is focused on addressing a clear drawback of existing immunotherapies,\u201d <\/i>says Prof Arkenau. \u201cMany existing antibody treatments have poor selective killing profiles, which can result in on-target, off-tumour effects and the discontinuation of treatment. I\u2019m proud to work alongside LabGenius as they use their platform\u2019s predictive power to identify non-intuitive antibody designs that perform well across multiple therapeutically valuable properties, including selective killing.\u201d<\/i><\/p>\n

\nProf Greiff is an Associate Professor at the University of Oslo. His group<\/a> develops machine learning, computational and experimental tools for analysing antibody and T-cell repertoires to facilitate the in-silico<\/i> design of immune receptor-based immunodiagnostics and immunotherapeutics. Prof Greiff\u2019s experience in combining computational and experimental approaches for effective antibody analysis will enhance LabGenius\u2019 platform development efforts, whilst helping to continue to streamline their antibody discovery processes.<\/p>\n

\n\u201cThe team\u2019s approach to data generation is unique,\u201d<\/i> says Prof Greiff. \u201cML models are only as good as the data they\u2019re trained on, so LabGenius\u2019 focus on generating large amounts of disease-relevant proprietary data using functional cell-based assays is incredibly powerful. I\u2019m confident that the impressive pre-clinical results we\u2019re seeing in the lab will soon translate into breakthrough cancer treatments for patients.\u201d<\/i><\/p>\n

\nAbout LabGenius<\/b><\/p>\n

\nHeadquartered in London, LabGenius is a leading machine learning-driven protein engineering company. The company\u2019s core technology platform, EVA\u2122<\/i><\/b>, enables the rapid discovery of novel therapeutic antibodies. LabGenius\u2019 highly multidisciplinary team brings together the very best minds from the fields of computer science, robotic automation and synthetic biology.<\/p>\n

\nFor more information, please visit www.labgeni.us<\/a>, or connect on Twitter<\/a>, LinkedIn<\/a> and Medium<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nFor more information, please contact:<\/b>
For media enquiries, please contact Lucy Shaw at press@labgeni.us<\/a>
For business development, please contact James Field at partnerships@labgeni.us<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Prominent oncology clinician Prof Hendrik-Tobias Arkenau and computational antibody design expert Prof Victor Greiff will bolster LabGenius’ leadership in the field of machine learning-driven antibody discovery. LONDON–(BUSINESS WIRE)–#AI–LabGenius, a pioneer in the use of machine learning (ML) for antibody discovery, today announced that accomplished scientific leaders Hendrik-Tobias Arkenau, MD\/PhD\/FRCP, and Victor Greiff, PhD, will join … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-55482","format-standard","category-industry"],"yoast_head":"\nLabGenius Appoints Prof Hendrik-Tobias Arkenau and Prof Victor Greiff as Scientific Advisors - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LabGenius Appoints Prof Hendrik-Tobias Arkenau and Prof Victor Greiff as Scientific Advisors - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Prominent oncology clinician Prof Hendrik-Tobias Arkenau and computational antibody design expert Prof Victor Greiff will bolster LabGenius’ leadership in the field of machine learning-driven antibody discovery. LONDON–(BUSINESS WIRE)–#AI–LabGenius, a pioneer in the use of machine learning (ML) for antibody discovery, today announced that accomplished scientific leaders Hendrik-Tobias Arkenau, MD\/PhD\/FRCP, and Victor Greiff, PhD, will join ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-04T07:04:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230329005889\/en\/1751219\/21\/foto-werk_20170830_16570_%281%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"LabGenius Appoints Prof Hendrik-Tobias Arkenau and Prof Victor Greiff as Scientific Advisors\",\"datePublished\":\"2023-04-04T07:04:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\\\/\"},\"wordCount\":555,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230329005889\\\/en\\\/1751219\\\/21\\\/foto-werk_20170830_16570_%281%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\\\/\",\"name\":\"LabGenius Appoints Prof Hendrik-Tobias Arkenau and Prof Victor Greiff as Scientific Advisors - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230329005889\\\/en\\\/1751219\\\/21\\\/foto-werk_20170830_16570_%281%29.jpg\",\"datePublished\":\"2023-04-04T07:04:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230329005889\\\/en\\\/1751219\\\/21\\\/foto-werk_20170830_16570_%281%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230329005889\\\/en\\\/1751219\\\/21\\\/foto-werk_20170830_16570_%281%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LabGenius Appoints Prof Hendrik-Tobias Arkenau and Prof Victor Greiff as Scientific Advisors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LabGenius Appoints Prof Hendrik-Tobias Arkenau and Prof Victor Greiff as Scientific Advisors - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\/","og_locale":"en_US","og_type":"article","og_title":"LabGenius Appoints Prof Hendrik-Tobias Arkenau and Prof Victor Greiff as Scientific Advisors - Pharma Trend","og_description":"Prominent oncology clinician Prof Hendrik-Tobias Arkenau and computational antibody design expert Prof Victor Greiff will bolster LabGenius’ leadership in the field of machine learning-driven antibody discovery. LONDON–(BUSINESS WIRE)–#AI–LabGenius, a pioneer in the use of machine learning (ML) for antibody discovery, today announced that accomplished scientific leaders Hendrik-Tobias Arkenau, MD\/PhD\/FRCP, and Victor Greiff, PhD, will join ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-04T07:04:38+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230329005889\/en\/1751219\/21\/foto-werk_20170830_16570_%281%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"LabGenius Appoints Prof Hendrik-Tobias Arkenau and Prof Victor Greiff as Scientific Advisors","datePublished":"2023-04-04T07:04:38+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\/"},"wordCount":555,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230329005889\/en\/1751219\/21\/foto-werk_20170830_16570_%281%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\/","url":"https:\/\/pharma-trend.com\/en\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\/","name":"LabGenius Appoints Prof Hendrik-Tobias Arkenau and Prof Victor Greiff as Scientific Advisors - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230329005889\/en\/1751219\/21\/foto-werk_20170830_16570_%281%29.jpg","datePublished":"2023-04-04T07:04:38+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230329005889\/en\/1751219\/21\/foto-werk_20170830_16570_%281%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230329005889\/en\/1751219\/21\/foto-werk_20170830_16570_%281%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/labgenius-appoints-prof-hendrik-tobias-arkenau-and-prof-victor-greiff-as-scientific-advisors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"LabGenius Appoints Prof Hendrik-Tobias Arkenau and Prof Victor Greiff as Scientific Advisors"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55482","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55482"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55482\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55482"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55482"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55482"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}